Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
- Personal Care Products
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 5948
â€œProductsâ€ shall mean the following
(i) Levall 5.0 – Phenylephrine HCl 15mg, Guaifenesin 100mg, Hydrocodone Bitartrate 5mg;
(ii) Levall G – Pseudoephedrine HCl/90mg, Guaifenesin 400mg;
(iii) Levall 12 – Carbetapentane Tannate 30mg, Phenylephrine Tannate 30 mg; (iv) Levall Liquid – Phenylephrine HCl 15mg, Carbetapentane Citrate 25 mg, Guaifenesin 100mg;
(v) Lev/Pse/GG – Pseudoephedrine HCl/90mg, Guaifenesin 400mg (Levall G Generic);
(vi) Carb/Phenyl-12 – Carbetapentane Tannate 30 mg, Phenylephrine Tannate 30mg (Levall 12 Generic); and (vii) Any future product using the Product Intellectual Property, including, but not limited to, NDAs, product line extensions, ANDAs, 505(b)(2) applications or the like.
The LevallÂ® product line consists of various pharmaceutical products that provide relief from coughing, congestion and rhinitis associated with respiratory infections such as the common cold, influenza, bronchitis and sinusitis. The LevallÂ® License permits us to make, sell, market, distribute, import and otherwise transfer the LevallÂ® products on a worldwide basis. Our LevallÂ® product line currently consists of four products LevallÂ® 12, LevallÂ® Liquid, LevallÂ® 5.0 and LevallÂ® G. Our LevallÂ® product line offers different combinations of antihistamines, expectorants, decongestants and anti-tussives that are designed to provide symptomatic relief for several patient types with respiratory infections.
IPSCIO Record ID: 7082
Licensee and Licensor desire to settle fully and finally any and all disputes and claims currently between them, in accordance with the terms and conditions of this Settlement Agreement.
IPSCIO Record ID: 4239
Products means any product marketed and sold by the Licensee or its Affiliate or sublicensee under the Extendryl mark or that is substantially similar in formulation to any of the Extendryl products sold by Fleming, including any product line extensions.
Extendryl family of products are prescription respiratory medications indicated for the relief of respiratory congestion, allergic rhinitis, and vasomotor rhinitis.
IPSCIO Record ID: 7499
Licensed Productsâ€ shall mean the collective reference to (I) the Mutual 600 mg Guaifenesin Product, (ii) the Mutual 1200 mg Guaifenesin Product, and (ii) the Mutual Combination Guaifenesin Products, defined herein, as well as (iv) any other product containing guaifenesin that is made with the formulation set forth in the Mutual ANDA; and a â€œLicensed Productâ€ shall mean each of them.
â€œMutual 600 mg Guaifenesin Productâ€ shall mean (I) a formulation as defined in the Mutual ANDA containing a total of 600 mg of guaifenesin as its sole active ingredient, (ii) any similar formulation that does not require a new bioequivalence clinical study for FDA approval, or (iii) or any formulation for which Licensee provides Licensor with a certification letter pursuant to 21 U.S.C. Â§ 355(j)(2)(B) representing that said formulation is subject to this Agreement as a Licensed Product, but excluding in each case any Bilayered Products.
â€œMutual 1200 mg Guaifenesin Productâ€ shall mean (I) a formulation as defined in the Mutual ANDA containing a total of 1200 mg of guaifenesin as its sole active ingredient, (ii) any similar formulation that does not require a new bioequivalence clinical study for FDA approval, or (iii) any formulation for which Licensee provides Licensor with a certification letter pursuant to 21 U.S.C. Â§ 355(j)(2)(B) representing that said formulation is subject to this Agreement as a Licensed Product, but excluding in each case any Bilayered Products.
â€œMutual ANDAâ€ shall mean the Abbreviated New Drug Application No. 78-333.
â€œLicensed Patentsâ€ shall mean the (I) the Adams Patent and U.S. Patent Application No. 09/559,542 filed April 28, 2000, and any claims that issue from the Reexamination, and (ii) any U.S. reissue, reexamination, continuation, divisional or continuation-in-part thereof.
â€œAdams Patentâ€ shall mean U.S. Patent No. 6,372,252.
Licensor manufactures, markets and sells the pharmaceutical formulations containing 600 and 1200 mg of guaifenesin alone and in combination with other active ingredients under the brand names MucinexÂ® (guaifenesin 600 mg ER tablets), MucinexÂ® DM (guaifenesin 600 mg/pseudoephedrine 60 mg ER tablets), MucinexÂ® D (guaifenesin 600 mg/dextromethorphan 30 mg ER tablets) and HumibidÂ® (guaifenesin 1200 mg ER tablets) and plans to manufacture, market and sell future extended-release products containing guaifenesin (collectively â€œAdams Guaifenesin Productsâ€);
Licensor asserts that Licenseeâ€™s versions of MucinexÂ® and HumibidÂ® infringe Adamsâ€™ U.S. Patent No. 6,372,252 (the â€œAdams Patentâ€).
IPSCIO Record ID: 291111
Finished Dosage Products means products that contain active pharmaceutical ingredients and are in a form ready for sale to a final consumer, including, without limitation, a liquid suspension or tablet.
Licensor is the owner of the entire right, title and interest in, to and under Letters Patent of the United States [No. 5,599,846 granted February 4, 1997], directed to phenylephrine tannate compositions and Letters of Patent of the United States No. 5,663,415 granted September 2, 1997, directed to processes for producing tannate products (said patents collectively referred to as the Licensed Patents).
Tanafed is a liquid cold and allergy product primarily for children.
The compound has a general use as an antihistamine.